Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Imbruvica Ibrutinib
Imbruvica Ibrutinib Chronic Lymphocytic Leukemia (previously untreated) Reimburse with clinical criteria and/or conditions Complete Apr 20, 2016 Nov 3, 2016
Imbruvica Ibrutinib Mantle Cell Lymphoma (relapsed/refractory) Reimburse with clinical criteria and/or conditions Complete Jan 29, 2016 Jul 19, 2016
Imbruvica Ibrutinib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Imfinzi Durvalumab Unresectable Non-Small Cell Lung Cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete Sep 21, 2018 May 3, 2019
Inlyta Axitinib Metastatic Renal Cell Carcinoma Reimburse Complete Aug 16, 2012 Mar 7, 2013
Inlyta (RFA) Axitinib Metastatic Renal Cell Carcinoma Complete Apr 18, 2017
Inqovi Decitabine-Cedazuridine Myelodysplastic Syndromes (MDS) Active Oct 9, 2020
Istodax Romidepsin Peripheral T-Cell Lymphoma Reimburse with clinical criteria and/or conditions Complete Dec 1, 2014 May 19, 2015
Jakavi Ruxolitinib Polycythemia vera Reimburse with clinical criteria and/or conditions Complete Aug 27, 2015 Mar 3, 2016